The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.

Domenico MallardoRachel WoodfordAlexander M MenziesLisa ZimmerAndrew WilliamsonEgle RamelyteFlorentia DimitriouAlexandre WickyRoslyn WallaceMario MallardoAlessio CortelliniAlfredo BudillonVictoria AtkinsonShahneen SandhuMichielin OlivierReinhard DummerPaul LoriganDirk SchadendorfGeorgina V LongEster SimeonePaolo Antonio Ascierto

Published in: Journal of translational medicine (2023)

LAG3 inhibition for treating metastatic or unresectable melanoma has a reduced efficacy in patients with type 2 diabetes, possibly due to a low expression of LAG3 in tumor tissue. Higher level evidence should be obtained.

Keyphrases

poor prognosis
type diabetes
squamous cell carcinoma
small cell lung cancer
cardiovascular disease
locally advanced
glycemic control
liver metastases
skin cancer
metabolic syndrome
radiation therapy
adipose tissue
skeletal muscle
insulin resistance